Use of confirmatory factor analysis for the identification of new components of the metabolic syndrome: The role of plasminogen activator inhibitor-1 and Haemoglobin A1c

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 4, 2009, Pages 271-276

  Boronat, M ^a,b   Saavedra, P ^b   Varillas, V F ^c   Novoa F J ^a,b  

^a HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^c Hospital General de Fuerteventura   (Spain)

Author keywords

Confirmatory factor analysis; Glycated haemoglobin; Metabolic syndrome; Plasminogen activator inhibitor 1

Indexed keywords

BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; FACTORIAL ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; RISK ASSESSMENT; RISK FACTOR; SPAIN; STATISTICAL MODEL;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SPAIN;

EID: 67349210418     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.07.007     Document Type: Article

References (37)

1. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
2. Alberti K.G.M.M., Zimmet P.Z., and Shaw J.E. The metabolic syndrome: a new world-wide definition from the International Diabetes Federation consensus. Lancet 366 (2005) 1059-1062
3. Devaraj S., Rosenson R.S., and Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 33 (2004) 431-453
4. Ridker P.M., Wilson P.W.F., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2818-2825
5. Boronat M., Varillas V.F., Saavedra P., et al. Diabetes mellitus and impaired glucose regulation in the Canary Islands (Spain): prevalence and associated factors in the adult population of Telde, Gran Canaria. Diabet Med 23 (2006) 148-155
6. Marcus B.H., Morris J., Paffenbarger Jr. R.S., et al. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. J Am Med Assoc 273 (1995) 402-407
7. Matthews D.R., Hosker J.P., and Rudenski A.S. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
8. Pladevall M., Singal B., Williams L.K., et al. A single factor underlies the metabolic syndrome. Diabetes Care 29 (2006) 113-122
9. Neale M.C., Boker S.M., Xie G., and Maes H.H. Mx: statistical modeling. 5th ed. (2003), Department of Psychiatry, Richmond, VA
10. Hu L., and Bentler P.M. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model 6 (1999) 1-55
11. Browne M.W., and Cudeck R. Alternative ways of assessing model fit. In: Bollen K.A., and Long J.S. (Eds). Testing structural equation models (1993), Sage, Thousand Oaks, CA 136-162
12. Akaike H. Factor analysis and AIC. Psychometrika 52 (1987) 317-332
13. Fornell C., and Larcker D. Evaluating structural equation models with unobservable variables and measurement error. J Mark Res 18 (1981) 39-50
14. Marques-Vidal P., Mazoyer E., Bongard V., et al. Prevalence of insulin resistance syndrome in Southwestern France an its relationship with inflammatory and hemostatic markers. Diabetes Care 25 (2001) 1371-1377
15. Anand S.S., Yi Q., Gerstein H., et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108 (2003) 420-425
16. Lim H.S., Lip G.Y.H., and Blann A.D. Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J Clin Endocrinol Metab 89 (2004) 5377-5381
17. Wannamethee S.G., Lowe G.D.O., Shaper A.G., Rumley A., Lennon L., and Whincup P.H. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 181 (2005) 101-108
18. Mertens I., Verrijken A., Miciels J.J., Van der Planken M., Ruige J.B., and Van Gaal L.F. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 30 (2006) 1308-1314
19. Liao Y., Kwon S., Shaughnessy S., et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27 (2004) 978-983
20. Sierra-Johnson J., Johnson B.D., Allison T.G., Bailey K.R., Schwartz G.L., and Turner S.T. Correspondence between the adult treatment panel III criteria for metabolic syndrome and insulin resistance. Diabetes Care 29 (2006) 668-672
21. Mansfield M.W., Stickland M.H., and Grant J.P. PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. Thromb Haemost 77 (1997) 357-361
22. Festa A., D'Agostino R., Mykkänen L., et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different status of glucose tolerance. Arterioscler Thromb Vasc Biol 19 (1999) 562-568
23. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., and Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46 (1997) 860-867
24. Ma L.J., Mao S.L., Taylor K.L., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
25. Crandall D.L., Quinet E.M., El Ayachi S., et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 26 (2006) 2209-2215
26. Ingelsson E., Pencina M.J., Tofler G.H., et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. Circulation 116 (2007) 984-992
27. Festa A., D'Agostino Jr. R., Tracy R.P., and Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 51 (2002) 1131-1137
28. Kanaya A.M., Fyr C.W., Vittinghoff E., et al. Adipocytokines and incident diabetes mellitus in older adults. Arch Intern Med 166 (2006) 350-356
29. Meigs J.B., O'Donnell C.J., Tofler G.H., et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes. Diabetes 55 (2006) 530-537
30. 1c level and peripheral arterial disease. Diabetes Care 28 (2005) 1981-1987
31. Selvin E., Coresh J., Golden S.H., Boland L.L., Brancati F.L., and Steffes M.W. Atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes. The Atherosclerosis Risk in Communities study. Diabetes Care 28 (2005) 1965-1973
32. Sung K.C., and Rhee E.J. Glycated haemoglobin as a predictor for metabolic syndrome in non-diabetic Korean adults. Diabet Med 24 (2007) 848-854
33. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 2587-2593
34. Lawlor D.A., Ebrahim S., May M., and Smith G.D. (Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol 159 (2004) 1013-1018
35. Li C., and Ford E.S. Is there a single underlying factor for the metabolic syndrome in adolescents? A confirmatory factor analysis. Diabetes Care 30 (2007) 1556-1561
36. Stickland M.H., Patou R.C., and Wales J.K. Haemoglobin A1c concentrations in men and women with diabetes. Br Med J 289 (1984) 733
37. Perreault L., Ma Y., Dagogo-Jack S., et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care 31 (2008) 1416-1421